My shoes look forward
to taking a walk.
Since multiple sclerosis (MS) started to
slow down my walking, taking my dog for
a walk has been more challenging. Then I
heard about AMPYRA™ (dalfampridine),
an FDA-approved oral medication indicated
as a treatment to improve walking in
patients with MS. This was demonstrated
by an increase in walking speed.
Also, AMPYRA™ can be taken by people with any
of the major types of MS. That could be good
news for my shoes—and one of my best friends.
Take the next step and ask your doctor
if AMPYRA may be right for you.
For more information, go to
or call 1.888.881.1918.
IMPORTANT SAFETY INFORMATION:
Talk to your doctor about AMPYRA to learn if it is safe for you. Do not take it if you’ve ever had a seizure
or if you have certain types of kidney problems as this may increase your risk of seizure. Tell your doctor
if you have kidney problems.
Never take more than one tablet of AMPYRA twice a day (about 12 hours apart). Don’t take more than
2 tablets in a 24-hour period because it may increase the risk of seizures. If you miss a dose of AMPYRA
don’t make up the missed dose.
Do not take AMPYRA together with other aminopyridine medications, including compounded
4-aminopyridine (sometimes called 4-AP, fampridine).
AMPYRA may cause serious side effects, including kidney or bladder infections. The most common side
effects are urinary tract infection, trouble sleeping (insomnia), dizziness, headache, nausea, weakness,
back pain, and problems with balance. Tell your doctor if you have any of these side effects that bother
you or do not go away.
For more information, please refer to the Medication Guide. This important safety information is not
meant to replace discussions with your doctor. For more information call toll-free 1-888-881-1918.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
AMP YRA™ is a trademark of Acorda Therapeutics, Inc., and is manufactured under license from
Elan Pharma International Ltd. © 2010 Acorda Therapeutics, Inc. All rights reserved.